New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Nutrition 21 Initiates Diachrome Clinical Study to Evaluate Improvement in Blood Sugar Control in Children and Adults with Type 2 Diabetes

PURCHASE, N.Y.--(BUSINESS WIRE)--Sept. 10, 2002--
Confirmation of Benefits of Diachrome as a Pediatric Nutrition Therapy Could Represent a Significant New and Long-Term Market Opportunity

Nutrition 21 (NASDAQ: NXXI), announced today a clinical study to evaluate the ability of the Company's nutritional supplement, Diachrome(tm), to improve blood glucose control in children and adults with type 2 diabetes.

The research study is designed to confirm earlier findings that Diachrome, a patented combination of chromium picolinate and biotin, improves blood sugar control in people with diabetes. The study is being conducted by Paul Harmatz, MD and Catherine Egli, MD at Children's Hospital Oakland, in conjunction with researchers from the University of Massachusetts, UCLA and Baylor University.

The study will use a pharmaceutical model that tests new drugs for diabetes. Approximately 90 people with type 2 diabetes will be enrolled in this study, which will take one year to complete. Five patients are already enrolled.

Gail Montgomery, President and CEO of Nutrition 21 stated, "It is now estimated that more than 13% of all children between the ages of 6 and 19 are overweight, greatly increasing their risk of developing type 2 diabetes, formerly considered an adult onset disease. More than 90% of the children with type 2 diabetes do not respond to treatment with diet and exercise alone. While pharmacological treatments are recognized as necessary to control the blood sugar levels of these children, there is a reluctance to administer the available drugs due to concerns regarding the long-term side affects associated with chronic use at such an early stage of life. In addition, the high cost of these medications over a lifetime places an enormous burden on both the patient and our healthcare system. There is a substantial opportunity for non-pharmacological treatments if they can improve outcomes, reduce side effects, and/or lower the cost of care for these children.

"This is our fourth clinical study on the benefits of Diachrome in people with type 2 diabetes. Our data are showing that supplemental Diachrome can significantly promote healthy blood sugar and cholesterol levels. We are looking forward to the completion of this study to see if Diachrome will either reduce the need for or potentially lower the required dose of prescribed medications in pediatric populations. A follow-up study to determine whether or not Diachrome may be used as a monotherapy for these patients is also being planned," she concluded.

About Nutrition 21
Nutrition 21 is a leading developer and marketer of nutritional products whose health benefits have been substantiated by clinical research. The market leader in nutritional chromium, Nutrition 21 currently holds 35 patents for nutrition products, 22 for chromium compounds and their uses. More information is available at

Safe Harbor Provision
The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Forward-looking statements are based on the company's current expectations and are subject to market, competitive and regulatory factors and the other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission. Actual results can differ materially. The company makes no commitment to disclose any revisions to forward-looking statements.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.